Drug Profile

Hyaluronic acid - Chugai Pharmaceuticals

Alternative Names: NRD-101; Sodium hyaluronate - Chugai Pharmaceuticals; Suvenyl; Suvenyl Dispo

Latest Information Update: 05 Nov 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Chugai Pharmaceutical
Class Adjuvants; Antirheumatics; Eye disorder therapies; Glycosaminoglycans; Urologics
Mechanism of Action Hyaluronic acid replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Marketed Pain
Phase III Frozen shoulder
Discontinued Plantar fasciitis

Most Recent Events

26 Jul 2021 Phase III development is still ongoing for Frozen shoulder and Pain in China
26 Jul 2021 Chugai Pharmaceutical intends to submit application in Frozen shoulder and Pain in China in 2021
08 Jun 2016 Chemical information added

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com